We report a method for rapid, effective detection of both Cr(iii) and Cr(vi) (in the form of Cr(3+) and Cr2O7(2-), the main species of chromium in the natural environment) by making use of meso-2,3-dimercaptosuccinic acid (DMSA)-functionalized gold nanoparticles (Au NPs). The limit of detection (LOD) is 10 nM with the naked eye and the assay can be applied in detecting chromium in polluted soil from Yun-Nan Province in Southwest China. We use density functional theory to calculate the change of the Gibbs free energy (ΔG) of the interactions between the DMSA-Au NP system and various metal ions, which shows that DMSA-Au NPs have high specificity for both Cr(3+) and Cr2O7(2-).

Even though the gold lateral flow test (GLFT) is low-cost and allows for point-of-care testing (POCT), its intrinsic limitations including low sensitivity and incapability of quantification significantly hinder the clinical application of GLFT for assaying disease biomarkers. To improve the performance of the GLFT without sacrificing its simplicity, we develop a chemiluminescent-gold lateral flow test (C-mode GLFT) for quantitative and multiplex detection of disease biomarkers with an ultrahigh sensitivity at a picomolar level. Horseradish peroxidase (HRP) and antibody (Ab) are simultaneously labeled onto the surface of gold nanoparticles (AuNPs) to achieve a dual-readout (chemiluminescent and visual, C&V-mode GLFT). A red color appears at the test line caused by the accumulation of captured AuNPs in the presence of targets, while HRP on the surface of AuNPs catalyzes the chemiluminescence reaction of luminol to amplify the signal. C-mode GLFT is successfully used for detecting tumor biomarkers (alpha fetoprotein, AFP, and carcino embryonic antigen, CEA) and bacterial infection biomarkers (procalcitonin, PCT) in serum samples as well as whole blood. The excellent features of C-mode GLFT such as straightforward operation, ultrahigh sensitivity and quantitative detection, make it a promising platform for POCT of a variety of disease biomarkers in real samples.

Stacked paper skiving paves the way for industrial manufacturing of paper-based analytical devices for barcode assays.

This study reports a simple, rapid, low-cost, robust, and multiplexed barcoded paper-based assay (BPA) compatible with mobile devices. An inkjet printer and an XYZ dispensing platform were used to realize mass-manufacturing of barcoded paper-based analytical devices (BPADs) with high precision and efficiency. We designed a new group of barcodes and developed an application (APP) for the reading of the new code. The new barcodes possess a 16 times higher coding capacity than the standard Codabar code in our experiment on drug residue detection. The BPA system allows applications in the assays of blood-transmitted infections, drug residues in milk and multiplex nucleic acids. The whole detection process and the readout of the results can be completed within 10 minutes. The limit of detection for enrofloxacin (ENR) (8 ng mL) satisfies the requirements of drug residue monitoring. Its high rapidity, simplicity, efficiency and selectivity make the BPA system extremely suitable to be applied in rapid and on-site detection.